Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.

Abstract

Some chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitor (TKI) do not respond or relapse. BCR-ABL1 mutations are the principal cause of TKI resistance, but the kinetics of emerging mutations in CML patients treated with imatinib remain to be determined. To investigate the emergence dynamics of mutations and their effects on… (More)
DOI: 10.1016/j.leukres.2012.09.012

Topics

4 Figures and Tables

Cite this paper

@article{Shih2013EmergingKO, title={Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.}, author={Lee-Yung Shih and Ming-Chung Kuo and C. Joncheng Kuo and Tseng-Hsi Lin and Li-Yaun Bai and Tsai-Yun Chen and Ming-chung Wang and Tung-Liang Lin and Yii-Jenq Lan and Chih-Cheng Chen and Youngsen Yang and Pei-Ching Hsiao and Chang-Liang Lai and Chia-Hui Chang and Tung-Huei Lin}, journal={Leukemia research}, year={2013}, volume={37 1}, pages={43-9} }